Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dust mites

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    74 result(s) found for: Dust mites. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2011-002248-29 Sponsor Protocol Number: AL1009ac Start Date*: 2012-03-07
    Sponsor Name:Allergopharma Joachim Ganzer KG
    Full Title: A multicentre randomised placebo-controlled double-blind clinical trial for evaluation of the optimal dose for safety and efficacy of specific immunotherapy with an aluminium hydroxide-adsorbed All...
    Medical condition: Controlled allergic bronchial asthma + rhinitis/rhinoconjunctivitis induced by house dust mite
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-000820-27 Sponsor Protocol Number: MM09-SIT-013 Start Date*: 2016-02-16
    Sponsor Name:Inmunotek, S.L.
    Full Title: Double blind, placebo-controlled, dose finding, prospective, multicenter clinical trial for the treatment of rhinitis/rinoconjuntivitis against a mixture of Dermatophagoides pteronyssinus and Derma...
    Medical condition: Mites allergy
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004870 10020419 House dust mite allergy LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000870-79 Sponsor Protocol Number: 101-PG-PSC-186 Start Date*: 2012-02-17
    Sponsor Name:Laboratorios LETI, S.L.U.
    Full Title: Prospective study to evaluate the safety of a 4-month treatment with Depigoid® Dermatophagoides pteronyssinus or 50% Dermatophagoides pteronyssinus / 50% Dermatophagoides farinae (500 DPP/ml) in pa...
    Medical condition: Allergic rhinitis or rhinoconjunctivitis with or without mild persistent or intermittent asthma, to Dermatophagoides pteronyssinus or Dermatophagoides pteronyssinus and Dermatophagoides farinae.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10020419 House dust mite allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000617-20 Sponsor Protocol Number: SMART_2 Start Date*: 2013-08-23
    Sponsor Name:Lofarma S.p.A.
    Full Title: A Dose Finding Study of the Efficacy of LAIS® Mites Sublingual tablets in patients suffering from house dust mite-induced allergic rhinoconjunctivitis A prospective, double-blind, placebo-controlle...
    Medical condition: Patients suffering from allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003066-34 Sponsor Protocol Number: 101-PG-PSC-150 Start Date*: 2007-01-23
    Sponsor Name:LETI Pharma GmbH
    Full Title: A randomized, double blinded, placebo controlled multicenter study for the efficacy and safety of Depigoid® House dust mites (HDM) in patients suf-fering from moderate to severe atopic eczema.
    Medical condition: Moderate to severe atopic eczema with or without rhinitis and/or rhinoconjunctivitis caused by clinical relevant IgE-mediated sensitization against House dust mites (HDM) leading to aggravation of ...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003641 Atopic eczema LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-002047-18 Sponsor Protocol Number: SM/0044 Start Date*: 2015-01-14
    Sponsor Name:HAL Allergy B.V.
    Full Title: A randomized, double-blind, placebo-controlled study to determine tolerability and safety of different dosages of SUBLIVAC FIX Mite mixture in patients with allergic rhinitis / rhinoconjunctivitis ...
    Medical condition: Patients, 18-60 years of age, suffering from house dust mites-induced persistent allergic rhinitis/rhinoconjunctivitis with or without concomitant at least partly controlled asthma.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004870 10020419 House dust mite allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001454-77 Sponsor Protocol Number: VO57.07 Start Date*: 2007-09-12
    Sponsor Name:Stallergenes S.A
    Full Title: A randomised, double-blind, placebo-controlled, multi-national Phase II/III study of the safety and efficacy of two doses of sublingual immunotherapy (SLIT) administered as allergen-based tablets o...
    Medical condition: House dust mite allergic rhinitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001723 Allergic rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) FR (Completed) DE (Completed) ES (Completed) NL (Completed) SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000446-34 Sponsor Protocol Number: MT-18 Start Date*: 2020-07-14
    Sponsor Name:ALK-Abelló A/S
    Full Title: A 28-day, single-armed, open-label trial to evaluate safety of the house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet in adolescent subjects (12-17 years of age) with HDM allergic...
    Medical condition: Allergic rhinitis/rhinoconjunctivitis induced by house dust mite
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10020419 House dust mite allergy LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2018-004262-34 Sponsor Protocol Number: MM09-SIT-023 Start Date*: 2020-04-28
    Sponsor Name:Inmunotek, S.L.
    Full Title: Randomized, placebo-controlled, prospective clinical trial of efficacy and safety for the treatment of rhinitis/rhinoconjunctivitis and asthma against a mixture of Dermatophagoides pteronyssinus an...
    Medical condition: House dust mites allergy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10020419 House dust mite allergy LLT
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    21.1 100000004855 10034382 Perennial allergic rhinitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000971-97 Sponsor Protocol Number: AL-X-01 Start Date*: 2017-08-23
    Sponsor Name:ALK Abelló A/S
    Full Title: Safety and tolerability of shortened up-dosing with Alutard SQ
    Medical condition: Allergic rhinoconjunctivitis induced by grass pollen, birch pollen and house dust mites
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000014962 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-003634-14 Sponsor Protocol Number: 107-PR-PRI-185 Start Date*: 2012-02-17
    Sponsor Name:Laboratorios Leti, S.L.Unipersonal
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10020419 House dust mite allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-000934-11 Sponsor Protocol Number: Al0106ac Start Date*: 2006-08-11
    Sponsor Name:Alllergopharma Joachim Ganzer KG
    Full Title: A multicentre randomised placebo-controlled double-blind clinical trial for evaluation of safety and efficacacy of a specific immunotherapy with an aluminium hydroxide-adsorbed allergoid preparatio...
    Medical condition: IgE-mediated allergic disease in adults manifested as rhinitis/ rhinoconjunctivitis and/or allergic asthma bronchiale (GINA I and II) triggered by non eliminable house dust mite allergens.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-003892-35 Sponsor Protocol Number: AL 0104 av Start Date*: 2005-04-01
    Sponsor Name:ALLERGOPHARMA JOACHIM GANZER KG
    Full Title: A multicentre randomised placebo-controlled double-blind clinical trial for evaluation of safety and efficacy of specific immunotherapy with an aluminium hydroxide-adsorbed Allergoid Preparation of...
    Medical condition: IgE-mediated allergic disease in adults and children manifested as bronchial asthma (GINA II and III) +/-allergic rhinitis/rhinoconjunctivitis, triggered by non-eliminable house dust mite allergens.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000487-28 Sponsor Protocol Number: VO72.12 Start Date*: 2013-08-20
    Sponsor Name:STALLERGENES SA
    Full Title: A dose ranging study investigating the efficacy and safety of sublingual immunotherapy tablets of house dust mite allergen extracts in adults with house dust mite-associated allergic asthma
    Medical condition: house dust mite-associated allergic asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004870 10020419 House dust mite allergy LLT
    14.1 100000004855 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) GB (Completed) SK (Completed) DE (Completed) CZ (Completed) BE (Completed) ES (Ongoing) PL (Completed) BG (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003516-62 Sponsor Protocol Number: CYT003-QbG10 08 Start Date*: 2007-10-19
    Sponsor Name:Cytos Biotechnology AG
    Full Title: Double-blind, Placebo-controlled Study to Investigate an Immunomodulatory Therapy (CYT003-QbG10) in Adult Patients with Perennial Allergic Rhinoconjunctivitis.
    Medical condition: Adult patients with perennial allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039097 Rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Completed) LT (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003427-11 Sponsor Protocol Number: PRO-RCT-ACAROS-2018-01 Start Date*: 2021-09-15
    Sponsor Name:Probelte Pharma S.L.U.
    Full Title: Efficacy and safety assessment of a subcutaneous immunotherapy (Beltavac®) with polymerized allergenic extract from house dust mites in patients with allergic rhinitis/rhinoconjuntivitis
    Medical condition: Allergic rhinitis/ rhinoconjuntivitis associated or not with asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10001724 Allergic rhinitis (excl hay fever) LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000597-29 Sponsor Protocol Number: 2017-02-CHRMT Start Date*: 2021-06-02
    Sponsor Name:Centre Hospitalier Régional Metz-Thionville
    Full Title: Interest of Nasal Provocation Tests for Diagnosis of House Mites Allergic Rhinitis
    Medical condition: mite allergenic rhinitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014036-37 Sponsor Protocol Number: AL0907ac Start Date*: Information not available in EudraCT
    Sponsor Name:Allergopharma Joachim Ganzer KG
    Full Title: A multicentre randomised placebo-controlled double-blind clinical trial for evaluation of safety and efficacy of a specific immunotherapy with an aluminium hydroxide adsorbed allergoid preparation ...
    Medical condition: Immunoglobulin E (IgE)-mediated allergic disease in adults and adolescents manifested by allergic rhinitis/rhinoconjunctivitis with or without controlled allergic asthma bronchiale (Global Initiati...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10039085 Rhinitis allergic LLT
    12.0 10001705 Allergic asthma LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: PL (Prematurely Ended) BG (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-000560-22 Sponsor Protocol Number: MT-12 Start Date*: Information not available in EudraCT
    Sponsor Name:ALK-Abelló A/S
    Full Title: A one-year placebo-controlled phase III trial evaluating the efficacy and safety of the house dust mite (HDM) SLIT-tablet in children (5-11 years of age) with HDM allergic rhinitis/rhinoconjunctivi...
    Medical condition: Allergic rhinitis/rhinoconjunctivitis induced by house dust mites
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10020419 House dust mite allergy LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) SK (Completed) DE (Completed) PL (Completed) ES (Ongoing) BG (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2008-006261-81 Sponsor Protocol Number: PM/0028 Start Date*: 2009-06-24
    Sponsor Name:HAL Allergy
    Full Title: Dose Tolerability Study with High Dose PURETHAL Mites in Allergic Rhinitis / Rhinoconjunctivitis Patients. An open study to assess tolerability, safety and short-term efficacy of high dose PURETHA...
    Medical condition: Allergic (IgE-mediated) rhinitis / rhinoconjunctivitis triggered by house dust mites.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001725 Allergic rhinitis due to other allergen LLT
    9.1 10053713 Allergenic desensitisation procedure LLT
    9.1 10053741 Allergenic desensitization procedure LLT
    9.1 10001709 Allergic conjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 04:17:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA